Table 4.
Summary of uses of abrocitinib in other INDICATIONS (off-label)[13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39]
| Dermatosis | Study | Duration | Cases/Sex/Age (Years) | Abrocitinib dose | Results | Previous Treatment |
|---|---|---|---|---|---|---|
| Alopecia areata[13] | 2023 Huang et al. | >6 years | 1/M/11 | 100 mg QD | Great improvement after 4 months | Corticosteroids, minoxidil, glycyrrhizic acid, traditional Chinese medicine |
| Alopecia areata after DRESS[14] | 2023: Zhang et al. | >4 months | 1/F/30 | 100 mg QD for 2 months, 200 mg QD for 2 months, 100 mg QD for 2 months | Significant improvement after 6 months | Betamethasone, tofacitinib (5 mg daily for 2 months) |
| Eruptive pruritic papular porokeratosis[15] | 2023 Xia et al. | 60 years | 1/M/75 | 100 mg QD | Completely subsided after 1 month | Ketotifen fumarate, levocetirizine dihydrochloride, ebastine, prednisone acetate, tripterygium wilfordii, cyclosporine A |
| Hailey-Hailey disease[16] | 2023 Li et al. | 12 years | 1/M/41 | 100 mg QD | Evident clinical response after 4 weeks | Corticosteroids, antibiotics |
| Lichen sclerosus[17] | 2023 Bao et al. | 14–52 months | 10/7F, 3M/22-48 | 100 mg QD | All achieved disease control after 12 weeks | Corticosteroids, calcineurin inhibitors |
| Occupational airborne allergic contact dermatitis[18] | 2022 Baltazar et al. | 2 years | 1/M/37 | 100 mg QD | Complete clearance in 8 weeks | Desonide 0.05% cream, mometasone furoate 0.1% cream, dupilumab (300 mg every 2 weeks for 11 months) |
| Prurigo nodularis[19] | 2023 Vander Does et al. | 2 years | 1/F/62 | 100 mg QD | Complete resolution after 2 months | Dupilimab (300 mg every 2 weeks), ruxolitinib 1.5% cream, triamcinolone, crisaborole 2% ointment |
| Netherton syndrome[20] | 2023 Zheng et al. | 20 years | 1/F/28 | 200 mg QD for 1 week, 100 mg QD | Significant improvement after 3 weeks | Emollients, corticosteroids, methotrexate, cyclosporine, secukinumab, dupilumab |
| Oral lichen planus[21] | 2023 Solimani et al. | NR | 1/M/58 | 200 mg QD for 12 weeks 100 mg QD | Good clinical response after 12 weeks | NR |
| Pyoderma gangrenosum[22] | 2023 Chen et al. | >1 years | 1/M/16 | 100 mg QD | Significant improvement after 4 weeks | Doxycycline, isotretinoin, glucocorticoids, cyclosporine A |
| Livedoid vasculopathy[22] | 2023 Chen et al. | >2 years | 1/F/31 | 100 mg QD for 4 weeks, 100 mg every 2 days | Complete remission after 6 weeks | Glucocorticoids, thalidomide, hydroxychloroquine, doxycycline, cyclosporine A, vitamin C |
| Cutaneous lichen amyloidosis[23] | 2023 Bai et al. | 3 years/5 years | 2/F, M/53, 59 | 100 mg QD for 4 months, once 3 days/100 mg QD for 9 weeks, once 2 days | Improved noticeably after 4 months/improved markedly after 8 weeks | Antihistamines, corticosteroids, clobetasol propionate and all-trans retinoic acid/antihistamines, corticosteroid, cryotherapy, UVB |
| Hidradenitis suppurativa[22] | 2023 Chen et al. | 3 years | 1/M/17 | 100 mg QD for 4 weeks, 100 mg once every 2 days | Complete remission after 6 weeks | Glucocorticoids, doxycycline |
| Granulomatous Rosacea[24] | 2023 Ren et al. | 1 month | 1/F/53 | 100 mg QD for 20 weeks | Within a week of starting the medication, the patient’s burning sensations markedly subsided. After 20 weeks of treatment and subsequent follow-ups, she experienced significant improvements in erythema, swelling, and capillary dilatation | |
| Nipple and areola eczema[25] | 2023 Teng et al. | >10 years | 1/M/28 | 100 mg QD for 12 weeks | Remarkable cure and no relapse 20 weeks after stopping treatment | Moisturizers, corticosteroids, calcineurin inhibitors, UVA1 phototherapy |
| Necrobiosis lipoidica[26] | 2023 Arnet et al. | >10 years | 1/F/53 | 200 mg QD for 11 weeks, 100 mg QD | Improvement after 11 months | Steroids, calcineurin inhibitors, psoralen-UVA, fumarate, hydroxychloroquine |
| Non- Segmental Vitiligo[27] | 2024 Satkunanathan et al. | 3 months | 1/M/61 | Abrocitinib 100 mg QD for 2 months | Significant repigmentation, no noted side effects, and no recurrence or progression of vitiligo patches | Tacrolimus 0.1% ointment to be applied twice a day (BID) oral mini-pulse prednisone 10 mg 2 consecutive days per week |
| Mucous Membrane Pemphigoid[28] | 2024 Teng et al. | 6 months | 1/F/62 | Abrocitinib 100 mg QD for 1 month then alternate day for 1 month | Two weeks later, the oral erosions had mostly subsided; 4 weeks later, they had disappeared without any accompanying pain and discomfort and the skin blisters were mostly dry | High-potency topical corticosteroid and topical tacrolimus |
| Perioral Dermatitis[29] | 2023 Teng et al. | 1 year | 1/M/26 | Abrocitinib 100 mg QD for 12 weeks | Rapid alleviation of pruritus and the complete disappearance of skin lesions after 2 weeks | Moisturizers, topical calcineurin inhibitors, oral tetracycline antibiotics (like doxycycline and minocycline), and hydroxychloroquine |
| Dupilumab-associated head and neck dermatitis[30] | 2024 Santosa et al. | 2 51/F 41/M | Abrocitinib 200 mg QD for 4 weeks | Improvement likely attributed to both discontinuation of dupilumab as well as effect of abrocitinib | Mometasone 0.1% cream and protopic 0.1% ointment to the face whilst continued on dupilumab, baricitinib Topical miconazole did not lead to any improvement. Dupilumab was discontinued and he was switched to baricitinib 4 mg | |
| Steroid-induced Rosacea[31] | 2023 Xu et al. | 1–2 years | 4 1–55/F 2,3,4-35/F | Abrocitinib 100 mg QD | After 2 weeks of treatment, the papules and facial erythema had improved significantly in all cases | Hydroxychloroquine, macrolide antibiotics, and a small dose of betamethasone intramuscularly |
| Granuloma Annulare[32] | 2024 Liu et al. | 1 year | 1/29/F | Abrocitinib at 150 mg QD | Two weeks, the patient experienced thinning of the plaques, and after 6 weeks, substantial improvement was observed with no new lesions | Oral cyclosporine (50 mg twice daily) and hydroxychloroquine (0.2 g twice daily) |
| Chronic Actinic Dermatitis[33] | 2023 Jin et al. | 18 years | 1/70/M | Abrocitinib 100 mg QD | Remarkable cleating of hypertrophic lesions at 6 weeks | NR |
| Bullous Pemphigoid[34] | 2024 Jiang et al. | 2 52/F 83/M | Abrocitinib 100 mg QD | Complete resolution | Minocycline, glucocorticoids, cyclophosphamide 60 mg methylprednisolone and cyclosporine | |
| Post-Hyaluronic Acid Filler Reaction[35] | 2024 Lopez et al. | 6 weeks | 1/55/F | Abrocitinib 100 mg QD | Marked improvement in itch and reduction in swelling within 14 days of starting the abrocitinib. At the 2-month follow-up, the edema had resolved with further improvement in some of the nodules as well as pruritus | Cephalexin, amoxicillin, clavulanate, and clarithromycin as well as two separate week-long courses of a methylprednisolone taper |
| Alopecia areata and AD[36] | 2022 Bennett et al. | NR/NR | 2/M, F/33, 46 | 100 mg or 200 mg QD/100 mg or 200 mg QD | Complete remission after 14 weeks/complete remission after 24 weeks | NR/NR |
| Alopecia areata[37] | 2022 Zhao et al. | 3 years | 1/F/14 | 200 mg QD | Completely relieved after 2 years | Steroids, antihistamines, Chinese acupuncture treatments |
| Plasma cell balinitis[38] | 2024: Xiong et al. | 8 months | 1/M/50 | 100 mg QD | Complete remission was achieved within the following 1 month | 0.03% tacrolimus ointment, 0.05% fluticasone propionate ointment, and 0.1% esacridine solution |
| Pityriasis Rubra Pilaris[39] | 2024 Li et al. | 0.5-11 years | 5 (2 F,3M) 27–78 years | 100 mg QD | Following a 12-week course of treatment, almost all patients attained complete clearance of the lesions | One patient had previously been treated with secukinumab and ixekizumab, while another patients received treatment with apremilast or acitretin |